Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $0.558
America/New_York / 31 des 1970 @ 19:00
RATING 2022-08-05 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
Revenue | n/a | |||||
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.936 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.33x |
Company: PE -1.936 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.337 - 0.779 ( +/- 39.63%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-06-06 | Matthews Christine | Sell | 82 | Common Stock |
2022-06-06 | Lo Steven | Sell | 442 | Common Stock |
2022-03-31 | Matthews Christine | Sell | 8 116 | Common Stock |
2022-03-31 | Kellerman Donald J | Sell | 4 006 | Common Stock |
2022-03-31 | Lo Steven | Sell | 23 633 | Common Stock |
INSIDER POWER |
---|
-100.00 |
Last 98 transactions |
Buy: 6 809 170 | Sell: 191 091 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.558 (0.00% ) |
Volume | 1.155 mill |
Avg. Vol. | 5.36 mill |
% of Avg. Vol | 21.54 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.